Please use this identifier to cite or link to this item: doi:10.22028/D291-39940
Title: The 3q Oncogene SEC62 Predicts Response to Neoadjuvant Chemotherapy and Regulates Tumor Cell Migration in Triple Negative Breast Cancer
Author(s): Radosa, Julia C.
Kasoha, Mariz
Doerk, Merle
Cullmann, Annika
Kaya, Askin C.
Linxweiler, Maximilian
Radosa, Marc P.
Takacs, Zoltan
Tirincsi, Andrea
Lang, Sven
Jung, Martin
Puppe, Julian
Linxweiler, Barbara
Wagner, Mathias
Bohle, Rainer M.
Solomayer, Erich-Franz
Zimmermann, Julia S. M.
Language: English
Title: International Journal of Molecular Sciences
Volume: 24
Issue: 11
Publisher/Platform: MDPI
Year of Publication: 2023
Free key words: triple-negative breast cancer
neoadjuvant chemotherapy
oncogene SEC62
tumor pathogenesis
translational research
tumor cell migration
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: In the absence of targeted treatment options, neoadjuvant chemotherapy (NACT) is applied widely for triple-negative breast cancer (TNBC). Response to NACT is an important parameter predictive of oncological outcomes (progression-free and overall survival). An approach to the evaluation of predictive markers enabling therapy individualization is the identification of tumor driver genetic mutations. This study was conducted to investigate the role of SEC62, harbored at 3q26 and identified as a driver of breast cancer pathogenesis, in TNBC. We analyzed SEC62 expression in The Cancer Genome Atlas database, and immunohistologically investigated SEC62 expression in pre- and post-NACT tissue samples from 64 patients with TNBC treated at the Department of Gynecology and Obstetrics/Saarland University Hospital/Homburg between January 2010 and December 2018 and compared the effect of SEC62 on tumor cell migration and proliferation in functional assays. SEC62 expression dynamics correlated positively with the response to NACT (p ≤ 0.01) and oncological outcomes (p ≤ 0.01). SEC62 expression stimulated tumor cell migration (p ≤ 0.01). The study findings indicate that SEC62 is overexpressed in TNBC and serves as a predictive marker for the response to NACT, a prognostic marker for oncological outcomes, and a migration-stimulating oncogene in TNBC.
DOI of the first publication: 10.3390/ijms24119576
URL of the first publication:
Link to this record: urn:nbn:de:bsz:291--ds-399409
ISSN: 1422-0067
Date of registration: 12-Jun-2023
Faculty: M - Medizinische Fakultät
Department: M - Frauenheilkunde
M - Hals-Nasen-Ohrenheilkunde
M - Innere Medizin
M - Medizinische Biochemie und Molekularbiologie
Professorship: M - Prof. Dr. Rainer M. Bohle
M - Prof. Dr. Martin Van der Laan
M - Prof. Dr. Bernhard Schick
M - Prof. Dr. E.-F. Solomayer
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
ijms-24-09576-v2.pdf2,94 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons